Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.
about
Aflibercept for neovascular age-related macular degenerationBlue-light filtering intraocular lenses (IOLs) for protecting macular healthAflibercept for neovascular age-related macular degenerationSystemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationSystemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationTargeting MAPK Signaling in Age-Related Macular DegenerationBirdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatmentEclectic Ocular Comorbidities and Systemic Diseases with Eye Involvement: A ReviewRelationship between Oxidative Stress, Circadian Rhythms, and AMDAflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degenerationAnxiety and depression in patients with advanced macular degeneration: current perspectivesGeographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospectsCurrent therapeutic developments in atrophic age-related macular degenerationEffects of Vitreomacular Adhesion on Age-Related Macular DegenerationParainflammation, chronic inflammation, and age-related macular degenerationPolypoidal Choroidal Vasculopathy in AsiansTapping Stem Cells to Target AMD: Challenges and ProspectsNLRP3 Inflammasome and Pathobiology in AMDInter-Ethnic/Racial Facial Variations: A Systematic Review and Bayesian Meta-Analysis of Photogrammetric StudiesManagement of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in developmentMesenchymal stem cell therapy in retinal and optic nerve diseases: An update of clinical trialsEarly detection of age related macular degeneration: current statusThe stereotypical molecular cascade in neovascular age-related macular degeneration: the role of dynamic reciprocityExploiting metabolic and antioxidant pathways to maintain vision in blinding diseaseEpidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors.Association of Age Related Macular Degeneration and Age Related Hearing Impairment.An Eye on Age-Related Macular Degeneration: The Role of MicroRNAs in Disease Pathology.Intakes of Lutein, Zeaxanthin, and Other Carotenoids and Age-Related Macular Degeneration During 2 Decades of Prospective Follow-up.The Evolution of the Plateau, an Optical Coherence Tomography Signature Seen in Geographic Atrophy.Oxidative stress affects retinal pigment epithelial cell survival through epidermal growth factor receptor/AKT signaling pathway.The complexities underlying age-related macular degeneration: could amyloid beta play an important role?Recent advances and future directions for the pharmacogenetic basis of anti-VEGF treatment response in neovascular age-related macular degenerationHuman plasma metabolomics in age-related macular degeneration (AMD) using nuclear magnetic resonance spectroscopy.Magnetic nanoparticles conjugated with "RPE cell -MCP-1 antibody -VEGF antibody" compounds for the targeted therapy of age-related macular degeneration: a hypothesisIntravitreal use of bone marrow mononuclear fraction containing CD34+ stem cells in patients with atrophic age-related macular degenerationThe Association between Age-Related Macular Degeneration and the Risk of Mortality.Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration.Altered bioenergetics and enhanced resistance to oxidative stress in human retinal pigment epithelial cells from donors with age-related macular degenerationNeovascular Age-Related Macular Degeneration in the Very Old (≥90 Years): Epidemiology, Adherence to Treatment, and Comparison of Efficacy.Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases
P2860
Q24186157-6F51F6EC-B201-45F2-995F-916A1B45E4D8Q24188090-C76196EE-0D53-413D-AB85-8BB66828C797Q24193255-51409DD9-AC8C-435A-831C-2E146CB78F9AQ24193614-12CF1D05-D2D8-42A9-8F00-4EAE46312B31Q24195003-A4359320-8974-4ACF-A916-BE0329A6C246Q26744185-DA24A904-E8BF-44F0-A07A-9DBEC939D595Q26749730-1057BF7C-B433-43CD-9A6E-8022C88B2087Q26751127-F9EB5D34-6D47-4EE6-8B98-05D51B465164Q26765278-2F94260F-7098-461D-8BB3-4EDB1BB4408AQ26771522-36F57BE1-BFE9-4051-9430-B64C05923BA5Q26772029-ECB983AD-3162-4952-892B-4D03B393FED0Q26774188-909814CE-C417-4B2C-8C38-FE795F27E6ABQ26778247-B5E52E31-73CC-42F4-AF61-76F40A8EE73DQ26783389-161CB0C3-5674-45EE-9762-BAA842D49B51Q26796268-5A2F6BB8-504C-4D7B-B138-1EF2A16C9797Q26799548-255D002A-E8DB-410F-897D-3C395C5C7CC5Q26799625-B2D883EC-1833-49D0-8713-1727CC48D4C4Q26799766-01AA9061-C9FE-4E0E-8D67-CC4C25587456Q26801563-126B4CA6-E3E6-4FB2-89A0-E6BAD5512B4FQ26824335-2FBFBEDB-13EE-4349-AFFB-120C6ABDE390Q28072497-5AE67767-3560-4C8C-9A40-C464AFE73D7AQ28076117-E70DA633-F194-4646-AA35-357685D7C71BQ28085495-DB0231A3-7BC5-4408-9862-493FBC82ECF7Q28391771-2119E1D5-A2FF-4493-A304-457F20FDE841Q30239897-17747930-DDC0-4666-BCBE-F4695E95B909Q30383601-40E8C619-111E-43B2-A316-7EB642D3E7DAQ30489873-4103C6D0-73F8-47E0-89AD-7B6A28A28D27Q30829406-9EE5395D-4C0E-4520-8227-6F54AECF7E1AQ30847480-6AD38CCD-617E-4BDD-8192-9849C98F607DQ33607708-EE6C6CB1-E874-46F2-BBE5-CC3112271618Q33702571-A57F144A-AF5A-4D96-B492-D44DAD80DE60Q33702577-3B5A3EF5-ACD7-49B1-BBCD-DB503E51C7FEQ33703808-FEF3A1C6-E285-48A5-BFE0-BC2F0A9FB1D5Q33706139-B2E08D39-CA24-4478-9A96-5FF56F5820B3Q33739755-FE65E513-2107-4D79-A983-E78E9740E169Q33747947-7BD37392-13D4-4067-A703-91B446F80EBAQ33758281-738D9E41-0CE1-4ACE-AAE6-9CB774C1E257Q33784315-3FB755D7-5F9F-488F-A3D8-788FDFC45AFEQ33808827-7845F5E1-0051-4C4A-A549-F59A089BDE96Q33840787-6D0677E4-14C9-4265-AC22-3B5F0A83C534
P2860
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Global prevalence of age-relat ...... atic review and meta-analysis.
@en
type
label
Global prevalence of age-relat ...... atic review and meta-analysis.
@en
prefLabel
Global prevalence of age-relat ...... atic review and meta-analysis.
@en
P2093
P1476
Global prevalence of age-relat ...... matic review and meta-analysis
@en
P2093
Chui Ming G Cheung
Ronald Klein
Tien Yin Wong
Wan Ling Wong
P304
P356
10.1016/S2214-109X(13)70145-1
P577
2014-01-03T00:00:00Z